3SBio Inc., a biotechnology company, focuses on the research, development, manufacture, and marketing of biopharmaceutical products primarily in the People’s Republic of China. Its products are designed to address unmet medical needs in nephrology, oncology, supportive cancer care, inflammation, and infectious diseases. The company’s principal products include EPIAO, an injectable recombinant human erythropoietin to stimulate the production of red blood cells in patients with anemia and to reduce the need for blood transfusions; and TPIAO, a recombinant human thrombopoietin product to treat chemotherapy-induced thrombocytopenia, a deficiency of platelets. 3SBio also offers protein-based therapeutics, such as Intefen, a recombinant human interferon alpha-2a product for malignancies of the lymphatic or hematopoietic system, and viral infectious diseases; and Inleusin, a recombinant human interleukin-2 product for renal cell carcinoma, metastatic melanoma, and thoratic fluid build-up caused by cancer and tuberculosis. In addition, it markets Tietai Iron Sucrose Supplement, an in-licensed product for the treatment of anemia. The company’s product pipeline comprises Ferumoxytol, a next generation intravenous iron; a high dose (36,000 IU/vial) formulation EPIAO; and NuPIAO, a second-generation EPIAO product candidate. Its product pipeline also consists of NuLeusin, a next-generation Inleusin product candidate; TPIAO for idiopathic thrombocytopenic purpura; a human papilloma virus vaccine to prevent cervical cancer; and an anti-TNF humanized monoclonal antibody product candidate for rheumatoid arthritis and other autoimmune diseases. 3SBio sells its products through distributors to hospitals, clinics, and dialysis centers, as well as through distribution agreements with local agents. It has a development and commercialization agreement with AMAG Pharmaceuticals, Inc. for ferumoxytol. The company was founded in 1993 and is based in Shenyang, the People’s Republic of China.
